Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCAR33 in Relapsed/Refractory AML Post-AlloHCT
NCT05984199Phase 2Terminated
- Sponsor
- Vor Bio
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD33 CAR-T in acute myeloid leukemia (AML), sponsored by Vor Bio. Started Dec 2023; status: terminated.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05984199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984199.